Loading...
Header Logo
Keywords
Last Name
Institution

ERNEST HAWK

TitleProfessor
InstitutionMD Anderson
DepartmentClinical Cancer Prevention
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mackert M, Case K, Lazard A, Oh J, Hughes Wagner J, Hawk E, Cofer J, Hurst A, Elerian N, Lakey D. Building a health communication brand for University of Texas System tobacco control. J Am Coll Health. 2019 May-Jun; 67(4):291-298. PMID: 29952736.
      View in: PubMed
    2. Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. 2019 Apr; 42:296-303. PMID: 30905849.
      View in: PubMed
    3. Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. 2019 Mar 22; 58(13):4179-4183. PMID: 30680862.
      View in: PubMed
    4. Cunningham SA, Yu R, Shih T, Giordano S, McNeill LH, Rechis R, Peterson SK, Cinciripini P, Foxhall L, Hawk E, Shete S. Cancer-Related Risk Perceptions and Beliefs in Texas: Findings from a 2018 Population-Level Survey. Cancer Epidemiol Biomarkers Prev. 2019 Mar; 28(3):486-494. PMID: 30700446.
      View in: PubMed
    5. Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Davidson NE, Disis ML, DuBois RN, Szabo E, Giuliano AR, Hait WN, Lee JJ, Kensler TW, Kramer BS, Limburg P, Maitra A, Martinez ME, Rebbeck TR, Schmitz KH, Vilar E, Hawk ET. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila). 2018 12; 11(12):735-778. PMID: 30530635.
      View in: PubMed
    6. Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. 2018 09; 37(2-3):439-454. PMID: 30112590.
      View in: PubMed
    7. Frech S, Muha CA, Stevens LM, Trimble EL, Brew R, Perin DP, Luciani S, Mohar A, Piñeros M, Vidaurre T, Morgan DR, Hawk ET, Schmeler KM, Foxhall LE, Rabadan-Diehl C, Duran D, Rendler-Garcia M, Cazap EL, Santini L, Zoss W, Delgado LB, Pearlman PC, Given L, Hohman K, Lopez MS, Kostelecky B. Perspectives on Strengthening Cancer Research and Control in Latin America Through Partnerships and Diplomacy: Experience of the National Cancer Institute's Center for Global Health. J Glob Oncol. 2018 Sep; 4:1-11. PMID: 30241245.
      View in: PubMed
    8. Hawk E, Maresso KC, Brown P. NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question. J Natl Cancer Inst. 2018 Sep 01; 110(9):927-928. PMID: 29554350.
      View in: PubMed
    9. Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol. 2018 Aug 01; 4(8):1085-1092. PMID: 29710228.
      View in: PubMed
    10. Hernandez M, Hernández-Valero MA, García-Prieto C, Patterson DG, Hajek RA, Recinos I, Lopez DS, Li Y, Jones LA, Hawk E. A Pilot Study Evaluating Organochlorine and Organophosphate Pesticide Exposure in Children and Adolescents of Mexican Descent Residing in Hidalgo County, Texas. J Immigr Minor Health. 2018 Jul 31. PMID: 30066057.
      View in: PubMed
    11. Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev. 2018 07 01; 32(13-14):868-902. PMID: 29945886.
      View in: PubMed
    12. Foxhall L, Moreno M, Hawk E. MD Anderson's Population Health Approaches to Cancer Prevention. Tex Med. 2018 02 01; 114(2):34-41. PMID: 29393960.
      View in: PubMed
    13. Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017 11 15; 77(22):6119-6130. PMID: 28951454.
      View in: PubMed
    14. Gausachs M, Borras E, Chang K, Gonzalez S, Azuara D, Delgado Amador A, Lopez-Doriga A, San Lucas FA, Sanjuan X, Paules MJ, Taggart MW, Davies GE, Ehli EA, Fowler J, Moreno V, Pineda M, You YN, Lynch PM, Lazaro C, Navin NE, Scheet PA, Hawk ET, Capella G, Vilar E. Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis. Clin Cancer Res. 2017 Oct 01; 23(19):5936-5947. PMID: 28645942.
      View in: PubMed
    15. Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut. 2018 07; 67(7):1299-1305. PMID: 28607096.
      View in: PubMed
    16. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799. PMID: 28579181.
      View in: PubMed
    17. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017 06; 36(2):199-213. PMID: 28730545.
      View in: PubMed
    18. Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017 06; 36(2):289-303. PMID: 28762014.
      View in: PubMed
    19. Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Banfield E, Hawk ET, Chang S, Frazier-Wood AC. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart. 2017; 4(1):e000550. PMID: 28674622.
      View in: PubMed
    20. Hurd TC, Kaplan CD, Cook ED, Chilton JA, Lytton JS, Hawk ET, Jones LA. Building trust and diversity in patient-centered oncology clinical trials: An integrated model. Clin Trials. 2017 Apr; 14(2):170-179. PMID: 28166647.
      View in: PubMed
    21. Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatol. 2017 Feb 01; 153(2):228-229. PMID: 27829081.
      View in: PubMed
    22. Lopez MS, Baker ES, Milbourne AM, Gowen RM, Rodriguez AM, Lorenzoni C, Mwaba C, Msadabwe SC, Tavares JH, Fontes-Cintra G, Zucca-Matthes G, Callegaro-Filho D, Ramos-Martin D, Thiago de Carvalho I, Coelho R, Marques RM, Chulam T, Pontremoli-Salcedo M, Nozar F, Fiol V, Maza M, Arora S, Hawk ET, Schmeler KM. Project ECHO: A Telementoring Program for Cervical Cancer Prevention and Treatment in Low-Resource Settings. J Glob Oncol. 2017 Oct; 3(5):658-665. PMID: 29094102.
      View in: PubMed
    23. Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601. PMID: 27574101.
      View in: PubMed
    24. Maresso KC, Hawk E. Cancer Prevention Recommendations: Impact of Adherence. Semin Oncol Nurs. 2016 08; 32(3):306-13. PMID: 27539284.
      View in: PubMed
    25. Hawk ET. Ernest Hawk Discusses the NCI-Designated Cancer Centers' Joint Statement on the HPV Vaccine. Oncology (Williston Park). 2016 Jul; 30(7):599-600. PMID: 27422108.
      View in: PubMed
    26. Vilar E, Maresso KC, Hawk ET. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol. 2016 Jun 01; 2(6):770-1. PMID: 26939883.
      View in: PubMed
    27. Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila). 2016 06; 9(6):417-27. PMID: 27221540.
      View in: PubMed
    28. Hildebrandt MA, Reyes ME, Lin M, He Y, Nguyen SV, Hawk ET, Wu X. Germline Genetic Variants in the Wnt/ß-Catenin Pathway as Predictors of Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):540-6. PMID: 26809274.
      View in: PubMed
    29. Tsai KY, Hawk ET. When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prev Res (Phila). 2016 Feb; 9(2):125-7. PMID: 26714773.
      View in: PubMed
    30. Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Cunningham S, Zhao H, Hawk ET, Wagar E, Rodriguez A, Hamilton SR. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol. 2016 06; 45(3):713-713f. PMID: 26686840.
      View in: PubMed
    31. Umar A, Steele VE, Menter DG, Hawk ET. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol. 2016 Feb; 43(1):65-77. PMID: 26970125.
      View in: PubMed
    32. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin. 2015 Sep-Oct; 65(5):345-83. PMID: 26284997.
      View in: PubMed
    33. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29. PMID: 25836985.
      View in: PubMed
    34. Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65(2):286-95. PMID: 25792707.
      View in: PubMed
    35. Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient? JAMA. 2014 Sep 24; 312(12):1193-4. PMID: 25247511.
      View in: PubMed
    36. Akiyama J, Alexandre L, Baruah A, Buttar N, Chandra R, Clark AB, Hart AR, Hawk E, Kandioler D, Kappel S, Krishnadath SK, Sharma A, Singh I, Straub D, Triadafilopoulos G, Umar A, Wolf B. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci. 2014 Sep; 1325:108-26. PMID: 25266020.
      View in: PubMed
    37. Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in colorectal cancer: predicting more than risk? Cancer Prev Res (Phila). 2014 Oct; 7(10):969-72. PMID: 25070664.
      View in: PubMed
    38. Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila). 2014 Oct; 7(10):973-92. PMID: 25060262.
      View in: PubMed
    39. Satcher RL, Bogler O, Hyle L, Lee A, Simmons A, Williams R, Hawk E, Matin S, Brewster AM. Telemedicine and telesurgery in cancer care: inaugural conference at MD Anderson Cancer Center. J Surg Oncol. 2014 Sep; 110(4):353-9. PMID: 24889208.
      View in: PubMed
    40. Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS, Jones LA, Hurd TC, Rogers LM, Nguyen LH, Ahluwalia JS, Fouad M, Vickers SM. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement. Cancer. 2014 Apr 01; 120 Suppl 7:1113-21. PMID: 24643649.
      View in: PubMed
    41. Herbst RS, Hobin JA, Gritz ER. AACR celebrates 50 years of tobacco research and policy. Clin Cancer Res. 2014 Apr 01; 20(7):1709-18. PMID: 24691637.
      View in: PubMed
    42. Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2013 Dec; 34(12):2750-6. PMID: 23996928.
      View in: PubMed
    43. Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47. PMID: 23776098.
      View in: PubMed
    44. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79. PMID: 23726390.
      View in: PubMed
    45. Raju GS, Vadyala V, Slack R, Krishna SG, Ross WA, Lynch PM, Bresalier RS, Hawk E, Stroehlein JR. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med. 2013 Jun; 2(3):391-402. PMID: 23930215.
      View in: PubMed
    46. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205. PMID: 23466817.
      View in: PubMed
    47. Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Deng G, Djeu J, Dou J, Hawk E, Jayaram B, Jia L, Joshi R, Kararala M, Karunagaran D, Kucuk O, Kumar L, Malafa M, Samathanam GJ, Sarkar F, Siddiqi M, Singh RP, Srivastava A, White JD. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med. 2013 Feb; 2(1):108-15. PMID: 24279005.
      View in: PubMed
    48. Brenner DE, Hawk E. Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila). 2013 Feb; 6(2):71-3. PMID: 23333813.
      View in: PubMed
    49. Patterson SL, Colbert Maresso K, Hawk E. Cancer chemoprevention: successes and failures. Clin Chem. 2013 Jan; 59(1):94-101. PMID: 23150056.
      View in: PubMed
    50. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L, Hawk E, Wu X. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012 Oct 17; 104(20):1599-611. PMID: 23073549.
      View in: PubMed
    51. Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer. 2012 Dec 15; 118(24):6188-98. PMID: 22673945.
      View in: PubMed
    52. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3982-91. PMID: 22661538.
      View in: PubMed
    53. Cialdella-Kam L, Sabado P, Bispeck MK, Silverman S, Bernstein L, Krawiec V, Hawk E, O'Donnell JF. Implementing cancer prevention into clinical practice. J Cancer Educ. 2012 May; 27(2 Suppl):S136-43. PMID: 22367592.
      View in: PubMed
    54. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31. PMID: 22505654.
      View in: PubMed
    55. Lin J, Forman MR, Wang J, Grossman HB, Chen M, Dinney CP, Hawk ET, Wu X. Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. Int J Cancer. 2012 Oct 15; 131(8):1892-903. PMID: 22261697.
      View in: PubMed
    56. Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clin Ther. 2012 Mar; 34(3):569-79. PMID: 22386831.
      View in: PubMed
    57. Lin M, Eng C, Hawk ET, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin J. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis. 2012 Apr; 33(4):841-7. PMID: 22318908.
      View in: PubMed
    58. Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hafemeister L, Hawk E, Wu X, Dubois RN, Mishra L. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer. 2012 Jan; 3(1):16-22. PMID: 22893787.
      View in: PubMed
    59. Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila). 2012 Jan; 5(1):61-72. PMID: 22030088.
      View in: PubMed
    60. Wu X, Patterson S, Hawk E. Chemoprevention--history and general principles. Best Pract Res Clin Gastroenterol. 2011 Aug; 25(4-5):445-59. PMID: 22122762.
      View in: PubMed
    61. Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80. PMID: 21816845.
      View in: PubMed
    62. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila). 2011 Nov; 4(11):1728-35. PMID: 21778329.
      View in: PubMed
    63. Brewster AM, Patterson SL, Forman MR, Hughes-Halbert C, Limburg PJ, Ondrey FG, Paskett ED, Wetter DW, Hawk ET. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila). 2010 Aug; 3(8):1044-8. PMID: 20663980.
      View in: PubMed
    64. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86. PMID: 20651033.
      View in: PubMed
    65. Hawk E, Patterson S. Modelling a dream: the molecular prevention of pancreatic cancer. Gut. 2010 May; 59(5):566-8. PMID: 20427387.
      View in: PubMed
    66. Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2010 May; 3(5):588-96. PMID: 20403998.
      View in: PubMed
    67. Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Dinney CP, Hawk ET, Wu X. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila). 2010 Apr; 3(4):505-17. PMID: 20354165.
      View in: PubMed
    68. Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun; 105(6):1437-43. PMID: 20234350.
      View in: PubMed
    69. Hawk E, Patterson S. Aspirin: anticolorectal adenocarcinoma activity in the adjuvant arena? Future Oncol. 2010 Feb; 6(2):197-200. PMID: 20146578.
      View in: PubMed
    70. Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009 Jul 01; 69(13):5269-84. PMID: 19491253.
      View in: PubMed
    71. Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, Hawk E, Pinsky PF. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol. 2009 May; 7(5):568-74. PMID: 19418605.
      View in: PubMed
    72. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21. PMID: 19336730.
      View in: PubMed
    73. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun; 136(7):2127-2136.e1. PMID: 19233181.
      View in: PubMed
    74. Hawk E, Guillem JG. Improving the vision of colonoscopy: does the fine print really matter? Cancer Prev Res (Phila). 2008 Dec; 1(7):495-8. PMID: 19138997.
      View in: PubMed
    75. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5. PMID: 18990728.
      View in: PubMed
    76. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila). 2008 Nov; 1(6):393-5. PMID: 19138984.
      View in: PubMed
    77. Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, Leischow S, Grad O. The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res. 2008 Sep 15; 14(18):5707-13. PMID: 18794079.
      View in: PubMed
    78. Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res. 2008 Sep 15; 14(18):5672-7. PMID: 18794074.
      View in: PubMed
    79. Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, Viner J, Hautala J, Grad O. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res. 2008 Sep 15; 14(18):5664-71. PMID: 18612047.
      View in: PubMed
    80. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8. PMID: 18841250.
      View in: PubMed
    81. Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):21-31. PMID: 19138933.
      View in: PubMed
    82. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13. PMID: 18378608.
      View in: PubMed
    83. Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead? Am J Gastroenterol. 2008 Apr; 103(4):838-41. PMID: 18371147.
      View in: PubMed
    84. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 04; 99(7):545-57. PMID: 17405999.
      View in: PubMed
    85. Hawk E, Viner JL. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):185-7. PMID: 17301246.
      View in: PubMed
    86. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33. PMID: 17655039.
      View in: PubMed
    87. Hawk E, Viner JL. What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S6-9. PMID: 17178278.
      View in: PubMed
    88. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 05; 114(10):1028-35. PMID: 16943394.
      View in: PubMed
    89. Hawk ET, Viner JL. Do statins prevent cancer? Nat Clin Pract Oncol. 2006 Sep; 3(9):478-9. PMID: 16955084.
      View in: PubMed
    90. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84. PMID: 16943400.
      View in: PubMed
    91. Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, Denobile J, Soballe P, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev. 2006 Jul; 15(7):1382-91. PMID: 16835340.
      View in: PubMed
    92. Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006 Jul 01; 66(13):6851-60. PMID: 16818663.
      View in: PubMed
    93. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      View in: PubMed
    94. Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev. 2006 May; 15(5):1046-7. PMID: 16702392.
      View in: PubMed
    95. Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):101-11. PMID: 16456576.
      View in: PubMed
    96. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005 Dec; 5(12):930-42. PMID: 16341084.
      View in: PubMed
    97. Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, Caldwell KL, Dong Z, Taylor PR, Dawsey SM. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005 Sep; 129(3):863-73. PMID: 16143126.
      View in: PubMed
    98. Hawk E, Viner JL. Statins and cancer--beyond the "one drug, one disease" model. N Engl J Med. 2005 May 26; 352(21):2238-9. PMID: 15917390.
      View in: PubMed
    99. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17; 352(11):1071-80. PMID: 15713944.
      View in: PubMed
    100. Hawk E, Viner JL. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2):297-8. PMID: 15734949.
      View in: PubMed
    101. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005 Jan 10; 23(2):378-91. PMID: 15637400.
      View in: PubMed
    102. Hawk ET, Umar A, Richmond E, Viner JL. Prevention and therapy of colorectal cancer. Med Clin North Am. 2005 Jan; 89(1):85-110, viii. PMID: 15527810.
      View in: PubMed
    103. Hawk ET, Umar A, Lubet RA, Kopelovich L, Viner JL. Can animal models help us select specific compounds for cancer prevention trials? Recent Results Cancer Res. 2005; 166:71-87. PMID: 15648184.
      View in: PubMed
    104. Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Szabo E, Mayo J, Schellenberg R, Coldman A, Hawk E, Gazdar A. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004 Oct 01; 10(19):6502-11. PMID: 15475437.
      View in: PubMed
    105. Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, Garber JE, Hawk E, Ganz PA, Somerfield MR. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol. 2004 Oct 01; 22(19):3848-51. PMID: 15353541.
      View in: PubMed
    106. Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology. 2004 Sep; 127(3):838-44. PMID: 15362039.
      View in: PubMed
    107. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004 Sep-Oct; 24(5B):3177-84. PMID: 15510608.
      View in: PubMed
    108. Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Ondrey FG, Viner JL, Spechler SJ, Hawk ET, Brenner DE. Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1250-2. PMID: 15247138.
      View in: PubMed
    109. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7. PMID: 15184247.
      View in: PubMed
    110. Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention--an overview of the science. Gastroenterology. 2004 May; 126(5):1423-47. PMID: 15131803.
      View in: PubMed
    111. Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Phillips RK, Patterson S, Conrads TP, Veenstra TD, Greenwald P, Hawk ET, Ali IU. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 2004 Apr 15; 64(8):2904-9. PMID: 15087410.
      View in: PubMed
    112. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb 18; 96(4):261-8. PMID: 14970275.
      View in: PubMed
    113. Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer. 2004 02; 4(2):153-8. PMID: 14964310.
      View in: PubMed
    114. Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother. 2003 Dec; 4(12):2193-204. PMID: 14640918.
      View in: PubMed
    115. Hawk ET, Viner JL. Aspirin: still learning about the wonder drug. Gut. 2003 Nov; 52(11):1535-6. PMID: 14570718.
      View in: PubMed
    116. Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res. 2003 Sep 15; 63(18):5649-55. PMID: 14522879.
      View in: PubMed
    117. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev. 2003 Aug; 12(8):755-62. PMID: 12917207.
      View in: PubMed
    118. Umar A, Viner JL, Anderson WF, Hawk ET. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol. 2003 Aug; 26(4):S48-57. PMID: 12902856.
      View in: PubMed
    119. Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):593-6. PMID: 12869396.
      View in: PubMed
    120. Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003 Feb-Mar; 523-524:137-44. PMID: 12628511.
      View in: PubMed
    121. Hawk ET, Viner J, Richmond E, Umar A. Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif. 2003; 21:759-89. PMID: 15338773.
      View in: PubMed
    122. Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, Gordon G, Forastiere AA. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus. 2003; 16(3):177-86. PMID: 14641306.
      View in: PubMed
    123. Hawk ET, Viner JL, Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog Exp Tumor Res. 2003; 37:210-42. PMID: 12795057.
      View in: PubMed
    124. Viner JL, Umar A, Hawk ET. Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am. 2002 Dec; 31(4):971-99. PMID: 12489273.
      View in: PubMed
    125. Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 2002 Oct; 82(5):905-41. PMID: 12507200.
      View in: PubMed
    126. Anderson WF, Guyton KZ, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002 Aug 07; 94(15):1126-33. PMID: 12165637.
      View in: PubMed
    127. Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, Hawk E, Christen MO, Gazdar AF. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst. 2002 Jul 03; 94(13):1001-9. PMID: 12096085.
      View in: PubMed
    128. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002 Jun; 50(6):857-60. PMID: 12010890.
      View in: PubMed
    129. Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst. 2002 Apr 17; 94(8):545-6. PMID: 11959883.
      View in: PubMed
    130. Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol. 2002 Feb; 7(1):2-26. PMID: 11942045.
      View in: PubMed
    131. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des. 2002; 8(12):1035-62. PMID: 11945150.
      View in: PubMed
    132. Umar A, Viner JL, Hawk ET. The future of colon cancer prevention. Ann N Y Acad Sci. 2001 Dec; 952:88-108. PMID: 11795446.
      View in: PubMed
    133. Demark-Wahnefried W, Schildkraut JM. Correspondence re: E. Hawk, et al., Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):415-6. PMID: 11319187.
      View in: PubMed
    134. Dimitrov NV, Leece CM, Tompkins ER, Seymour E, Bennink M, Gardiner J, Crowell J, Hawk E, Nashawaty M, Bennett JL. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):201-7. PMID: 11303588.
      View in: PubMed
    135. Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol. 2001 Feb; 28(1):106-20. PMID: 11254870.
      View in: PubMed
    136. Hawk ET, Viner JL. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med. 2001 Jan 16; 134(2):158-60. PMID: 11177320.
      View in: PubMed
    137. Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ. Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ. 2001; 154:13-26. PMID: 11220652.
      View in: PubMed
    138. Precancerous lesions of the digestive tract. The 18th Annual Symposium of the European Cancer Prevention Organization. Maastricht, The Netherlands. 12-14 October 2000. Abstracts. Eur J Cancer Prev. 2000 Dec; 9(6):443-63. PMID: 11263399.
      View in: PubMed
    139. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs. 2000 Sep; 9(9):2121-38. PMID: 11060797.
      View in: PubMed
    140. Hawk ET, Lippman SM. Primary cancer prevention trials. Hematol Oncol Clin North Am. 2000 Aug; 14(4):809-30. PMID: 10949775.
      View in: PubMed
    141. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun 29; 342(26):1946-52. PMID: 10874062.
      View in: PubMed
    142. Hawk E, Viner JL, Lawrence JA. Biomarkers as surrogates for cancer development. Curr Oncol Rep. 2000 May; 2(3):242-50. PMID: 11122849.
      View in: PubMed
    143. Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 2000 May; 9(5):523-7. PMID: 10815699.
      View in: PubMed
    144. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000 Apr 01; 60(7):1864-70. PMID: 10766173.
      View in: PubMed
    145. Heath EI, Limburg PJ, Hawk ET, Forastiere AA. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Williston Park). 2000 Apr; 14(4):507-14; discussion 518-20, 522-3. PMID: 10826312.
      View in: PubMed
    146. Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000 Feb; 9(2):127-37. PMID: 10698472.
      View in: PubMed
    147. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000 02; 130(2S Suppl):467S-471S. PMID: 10721931.
      View in: PubMed
    148. van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000 Jan; 6(1):78-89. PMID: 10656435.
      View in: PubMed
    149. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer. 1999 Dec 01; 86(11 Suppl):2551-63. PMID: 10630181.
      View in: PubMed
    150. McCaskill-Stevens W, Hawk ET, Flynn PJ, Lippman SM. National Cancer Institute--supported cancer chemoprevention research: coming of age. J Clin Oncol. 1999 Nov; 17(11 Suppl):53-62. PMID: 10630263.
      View in: PubMed
    151. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999 May; 8(5):467-83. PMID: 10350444.
      View in: PubMed
    152. Lam S, leRiche JC, Zheng Y, Coldman A, MacAulay C, Hawk E, Kelloff G, Gazdar AF. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst. 1999 Apr 21; 91(8):691-6. PMID: 10218506.
      View in: PubMed
    153. Li H, Schut HA, Conran P, Kramer PM, Lubet RA, Steele VE, Hawk EE, Kelloff GJ, Pereira MA. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis. 1999 Mar; 20(3):425-30. PMID: 10190557.
      View in: PubMed
    154. Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD, DuBois RN. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis. 1999 Feb; 20(2):185-91. PMID: 10069452.
      View in: PubMed
    155. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, Sigman CC. Progress in cancer chemoprevention. Ann N Y Acad Sci. 1999; 889:1-13. PMID: 10668477.
      View in: PubMed
    156. Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, Fryer B, Church JM, Provencher K, Pamukcu R, Piazza G, Hawk E, Kelloff G, Elson P, van Stolk RU. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol. 1999; 470:45-53. PMID: 10709673.
      View in: PubMed
    157. Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem. 1998 Feb; 44(2):420-7. PMID: 9474054.
      View in: PubMed
    158. Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell JA, Hawk ET, Boone CW, Sigman CC. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1998 Jan; 7(1):65-78. PMID: 9456245.
      View in: PubMed
    159. Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC. Progress in clinical chemoprevention. Semin Oncol. 1997 Apr; 24(2):241-52. PMID: 9129692.
      View in: PubMed
    160. Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk ET, Steele VE, Lubet RA, Sigman CC. Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res. 1997; 396:159-83. PMID: 9108597.
      View in: PubMed
    161. Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev. 1996 Dec; 5 Suppl 2:79-85. PMID: 9061299.
      View in: PubMed
    162. Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Nayfield SG, Perloff M, Steele VE, Lubet RA. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park). 1996 Oct; 10(10):1471-84; discussion 1484-8. PMID: 8905841.
      View in: PubMed
    163. Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 1996 Jul; 17(7):1435-8. PMID: 8706245.
      View in: PubMed
    164. Hawk E, Prindiville S, Kelloff G. NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology. 1996 Feb; 110(2):654-5. PMID: 8566622.
      View in: PubMed
    165. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, Malone WF, Hawk ET, Sigman CC. New agents for cancer chemoprevention. J Cell Biochem Suppl. 1996; 26:1-28. PMID: 9154166.
      View in: PubMed
    166. Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Malone WF, Steele VE, Lubet RA, Sigman CC. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl. 1996; 25:1-14. PMID: 9027592.
      View in: PubMed
    167. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet RA, Greenwald P, Hawk ET, Fay JR, Sigman CC. Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ. 1996; (139):203-19. PMID: 8923032.
      View in: PubMed
    168. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl. 1996; 26:54-71. PMID: 9154168.
      View in: PubMed
    169. Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA, Sigman CC. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl. 1995; 23:1-9. PMID: 8747372.
      View in: PubMed
    170. Response to letter regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas" [2]. Circulation. 115.
    171. Cancer and the cyclo-oxygenase enzyme. American Journal of Cancer. 2:27-55.
    172. Introduction. Seminars in Oncology Nursing.
    173. Clinical development plans for cancer chemopreventive agents. Journal of Cellular Biochemistry. 63:72-315.
    174. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nature Communications. 7.
    175. Cancer prevention in developing countries. Salud Publica de Mexico. 58:93-96.
    176. Foreword. Unknown Journal.
    177. Series Foreword. Unknown Journal. 9781118501627:ix-x.
    178. Cancer Prevention, Screening, and Early Detection. 322-359.
    179. Cancer Chemoprevention.
    180. Primary Hepatic Cancer. 161-181.
    181. The authors reply [9]. New England Journal of Medicine. 355:2371-2372.
    182. Designing the chemoprevention trials of tomorrow. 265-284.
    183. Chemoprevention in hereditary colorectal cancer syndromes. Cancer. 86:1731-1743.
    184. Development of breast cancer chemopreventive drugs. Breast Journal. 1:271-283.
    185. Colorectal Cancer Prevention and Aging. 85-96.
    186. Cancer Prevention Recommendations. Seminars in Oncology Nursing. 32:306-313.
    187. Handbook of Gastrointestinal Cancer.
    188. Germline genetic variants in the Wnt/β-catenin pathway as predictors of colorectal cancer risk. Cancer Epidemiology Biomarkers and Prevention. 25:540-546.
    189. Genomic landscape of colorectal mucosa and adenomas. Cancer Prevention Research. 9:417-427.
    190. Surrogate endpoint biomarker (SEB) guided drug development. Clinical Pharmacology and Therapeutics. 61:165.
    HAWK's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description